CITATION REPORT List of articles citing

Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes

DOI: 10.1111/dom.13659 Diabetes, Obesity and Metabolism, 2019, 21 Suppl 2, 53-61.

Source: https://exaly.com/paper-pdf/73223727/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Effects of sodium-glucose cotransporter inhibitors on cardiorenal and metabolic systems: Latest perspectives from the outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 5-8	6.7	5
8	Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21 Suppl 2, 53-61	6.7	6
7	Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 540-548	6.7	12
6	Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index 127 kg/m. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2151-2160	6.7	9
5	Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?. Diabetes/Metabolism Research and Reviews, 2021 , 37, e3415	7.5	О
4	Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 2128-2136	14.6	5
3	The automated pancreas: A review of technologies and clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	1
2	The Role of SGLT Inhibitors with HCL Systems in Diabetes Treatment ${\rm I}$ is Continuous Ketone Monitoring the Solution ?.		
1	Sick day management in children and adolescents with diabetes.		1